key: cord-0913368-22b4t4wh
authors: Mukherjee, Santanu; Mazumder, Payal; Joshi, Madhvi; Joshi, Chaitanya; Dalvi, Sameer V.; Kumar, Manish
title: Biomedical application, Drug Delivery and Metabolic Pathway of Antiviral Nanotherapeutics for combating viral Pandemic: A Review
date: 2020-08-23
journal: Environ Res
DOI: 10.1016/j.envres.2020.110119
sha: a5c97abe51e9a1c67075637afc2e810b6a7b0d1f
doc_id: 913368
cord_uid: 22b4t4wh

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a neoteric virus belonging to the beta coronavirus class has created a global health concern, responsible for an outbreak of severe acute respiratory illness, the COVID-19 pandemic. Infected hosts exhibit diverse clinical features, ranging from asymptomatic to severe symptoms in their genital organs, respiratory, digestive, and circulatory systems. Considering the high transmissibility (R(0): ≤6.0) compared to Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV, the quest for the clinical development of suitable antiviral nanotherapeutics (NTPs) is incessant. We are presenting a systematic review of the literature published between 2003 and 2020 to validate the hypothesis that the pharmacokinetics, collateral acute/chronic side effects of nano drugs and spike proteins arrangement of coronaviruses can revolutionize the therapeutic approach to cure COVID-19. Our aim is also to critically assess the slow release kinetics and specific target site chemical synthesis influenced competence of NTPs and nanotoxicity based antiviral actions, which are commonly exploited in the synthesis of modulated nanomedicines. The pathogenesis of novel virulent pathogens at the cellular and molecular levels are also considered, which is of utmost importance to characterize the emerging nano-drug agents as diagnostics or therapeutics or viral entry inhibitors. Such types of approaches trigger the scientists and policymakers in the development of a conceptual framework of nano-biotechnology by linking nanoscience and virology to present a smart molecular diagnosis/treatment for pandemic viral infections.

The ongoing pandemic coronavirus disease outbreak (COVID-2019), stemming from the beta coronavirus class (SARS-CoV-2) causing severe acute respiratory syndrome (SARS), has polyethylene glycol (mPEG)-PLA, CLPM are found suitable for Hepatitis (B and C) virus The different forms of nanomaterials that are mostly used as antiviral agents depend largely on 144 the pathway of drug delivery system, which provide versatile forms of nano-based carriers 145 starting from complex, organic hybrid nanosystems to simple inorganic metallic composites. (Table 3 ). Viral binding of gp120 and CD4 through host cell surface receptor and photothermal 366 medium (regulation of cell pH) can be achieved in vitro (for HIV-1 virus with AuNPs) (Fig. 3) . embedded nanotherapeutics can be effectively used for SARS-CoV-2 control (Fig. 3) . 

Grass carp Reovirus VP7/DNA mediated inhibition Immunization 

Nanobiotechnology: cell membrane-based delivery 700 systems

Biomimetic nanotechnology 702 toward personalized vaccines

A pneumonia outbreak associated with a new 705 coronavirus of probable bat origin

Review of therapeutic agents for the treatment of COVID-19

J o u r n a l P r e -p r o o f n.a*-Not applicable, AuNPs-Gold Nanoparticles, AgNPs-Silver Nanoparticles, FeNPs-Iron Nanoparticles, SiNPs-Silica Nanoparticles, TiO 2 -Titanium nanoparticles, GO-Graphene oxides.J o u r n a l P r e -p r o o f